| NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals P Duewell, H Kono, KJ Rayner, CM Sirois, G Vladimer, FG Bauernfeind, ... Nature 464 (7293), 1357-1361, 2010 | 4163 | 2010 |
| Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome C Bauer, P Duewell, C Mayer, HA Lehr, KA Fitzgerald, M Dauer, ... Gut 59 (9), 1192-1199, 2010 | 901 | 2010 |
| Western diet triggers NLRP3-dependent innate immune reprogramming A Christ, P Günther, MAR Lauterbach, P Duewell, D Biswas, K Pelka, ... Cell 172 (1), 162-175. e14, 2018 | 881 | 2018 |
| RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells P Duewell, A Steger, H Lohr, H Bourhis, H Hoelz, SV Kirchleitner, ... Cell Death & Differentiation 21 (12), 1825-1837, 2014 | 208 | 2014 |
| Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer J Ellermeier, J Wei, P Duewell, S Hoves, MR Stieg, T Adunka, ... Cancer research 73 (6), 1709-1720, 2013 | 195 | 2013 |
| Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors C Bauer, P Duewell, HA Lehr, S Endres, M Schnurr Digestive diseases 30 (Suppl. 1), 82-90, 2012 | 171 | 2012 |
| NLRP3 inflammasome activation in inflammaging E Latz, P Duewell Seminars in immunology 40, 61-73, 2018 | 161 | 2018 |
| Impact of a new fusion receptor on PD-1–mediated immunosuppression in adoptive T cell therapy S Kobold, S Grassmann, M Chaloupka, C Lampert, S Wenk, F Kraus, ... Journal of the National Cancer Institute 107 (8), djv146, 2015 | 141 | 2015 |
| ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells P Duewell, U Kisser, K Heckelsmiller, S Hoves, P Stoitzner, S Koernig, ... The Journal of Immunology 187 (1), 55-63, 2011 | 141 | 2011 |
| T cells armed with CXC chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours S Lesch, V Blumenberg, S Stoiber, A Gottschlich, J Ogonek, BL Cadilha, ... Nature biomedical engineering 5 (11), 1246-1260, 2021 | 123 | 2021 |
| Joosten LAB, Groh LA, Riksen NP, Espevik T, Schlitzer A, Li Y, Fitzgerald ML, Netea MG, Schultze JL, Latz E. Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming A Christ, P Gunther, MAR Lauterbach, P Duewell, D Biswas, K Pelka, ... Cell 172 (1-2), 162-175, 2018 | 102 | 2018 |
| An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma C Jacobs, P Duewell, K Heckelsmiller, J Wei, F Bauernfeind, J Ellermeier, ... International Journal of Cancer 128 (4), 897-907, 2011 | 99 | 2011 |
| Interleukin-22 is frequently expressed in small-and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells S Kobold, S Völk, T Clauditz, NJ Küpper, S Minner, A Tufman, P Düwell, ... Journal of Thoracic Oncology 8 (8), 1032-1042, 2013 | 86 | 2013 |
| Inflammasome-dependent and-independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant NS Wilson, P Duewell, B Yang, Y Li, S Marsters, S Koernig, E Latz, ... The Journal of Immunology 192 (7), 3259-3268, 2014 | 77 | 2014 |
| Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma P Duewell, E Beller, SV Kirchleitner, T Adunka, H Bourhis, J Siveke, ... Oncoimmunology 4 (10), e1029698, 2015 | 61 | 2015 |
| Immunotherapy in tumors: Activated T cells as a new treatment modality S Kobold, P Duewell, M Schnurr, M Subklewe, S Rothenfusser, S Endres Deutsches Ärzteblatt International 112 (48), 809, 2015 | 57 | 2015 |
| RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade M Ruzicka, LM Koenig, S Formisano, DFR Boehmer, B Vick, EM Heuer, ... Leukemia 34 (4), 1017-1026, 2020 | 56 | 2020 |
| BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity ZA Bittner, X Liu, M Mateo Tortola, A Tapia-Abellán, S Shankar, ... Journal of Experimental Medicine 218 (11), e20201656, 2021 | 53 | 2021 |
| Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic … C Bauer, A Sterzik, F Bauernfeind, P Duewell, C Conrad, R Kiefl, ... Cancer Immunology, Immunotherapy 63, 321-333, 2014 | 48 | 2014 |
| High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy F Rataj, SJ Jacobi, S Stoiber, F Asang, J Ogonek, N Tokarew, BL Cadilha, ... British journal of cancer 120 (1), 79-87, 2019 | 46 | 2019 |
